Loading…
The gut microbiome is being investigated as a potential contributor to Autism Spectrum Disorder-related biology through microbial metabolites, immune signaling, gut-barrier integrity, inflammation, oxidative stress, and neuroimmune regulation.
Gastrointestinal problems are common in children with ASD and often correlate with symptom severity, supporting clinical interest in the gut–brain connection (1)
Animal studies suggest that microbiota-related mechanisms can influence abnormal metabolites and behavior, but animal findings do not establish causation in humans (2)
Earlier studies reported abnormal gut bacteria in children with ASD and proposed a relationship between dysbiosis and gastrointestinal or behavioral symptoms (1)
A large stool metagenomics study found only limited direct associations between microbiome composition and autism diagnosis. Stronger associations were observed with dietary traits, stool consistency, and age (3)
Romboutsia timonensis was the only taxon associated with ASD diagnosis in that study. The authors cautioned against claiming that the microbiome has a driving role in ASD (3)
Restricted interests and other autistic traits may be associated with a less-diverse diet. A less-diverse diet is, in turn, associated with lower gut-microbiome alpha diversity. This supports a model in which autism-related behavioral or phenotypic characteristics influence diet, and dietary patterns subsequently shape microbiome diversity (3)
Diet, prebiotics, probiotics, synbiotics, antibiotics, antifungals, and MTT can all influence the microbiome. Responses are likely to vary considerably from person to person (11).
Short-chain fatty acids (SCFAs), including butyrate, propionate, and acetate, can affect the gut, brain, behavior, and immune system (4, 5). In animal models, specific metabolites have improved social or sensorimotor abnormalities, suggesting possible mechanistic pathways (6). Beta-hydroxybutyrate was significantly decreased in the cerebrospinal fluid of patients with autistic regression. It remains unclear whether this reflects reduced production, increased consumption, or another mechanism (7)
Germ-free mice colonized with gut microbiota from autistic individuals developed ASD-like behaviors in one study; administration of specific metabolites improved social-behavior abnormalities (6). In a maternal immune-activation mouse model, Bacteroides fragilis improved communicative and sensorimotor behavioral defects (8). These findings support biological plausibility but cannot by themselves demonstrate that microbiome changes cause ASD in humans (6, 8)
In one study, oral non-absorbable antibiotic treatment temporarily improved gastrointestinal and ASD symptoms in children (1). The temporary nature of the improvement and the limited evidence base mean that such approaches should not be interpreted as established ASD treatments (1). Further controlled research is needed to distinguish effects on gastrointestinal symptoms from effects on core ASD characteristics.
Interventions targeting the gut microbiome -particularly microbiota transfer therapy (MTT), including fecal microbiota transplantation (FMT) - show promise for improving gastrointestinal symptoms in autism and potentially alleviating some neurobehavioral symptoms as well. However, these procedures are not yet established autism treatments (11).
The most plausible strategy may be restoring a more diverse, more typically developing microbial ecosystem rather than administering a single probiotic strain (11).
Current evidence remains preliminary. Studies are generally small, inconsistent, and often uncontrolled, limiting confidence about effectiveness, safety, and clinical relevance (11).
Larger, well-controlled, long-term studies are needed to determine who benefits, which microbial changes are crucial, and whether behavioral improvements are mediated by the microbiome (11).
Oral dysbiosis characterized by increased Streptococcus and reduced Prevotella has been proposed as a possible factor in ASD pathogenesis. Oral microbes may reach the gut through enteral or hematogenous routes, potentially worsening intestinal dysbiosis and systemic inflammation. Proposed downstream mechanisms include impaired gut-barrier integrity, lipopolysaccharide and cytokine signaling, oxidative stress, glial activation, and altered neurodevelopment. These mechanisms remain a developing research hypothesis (9).
Evidence supports an association among ASD, gastrointestinal symptoms, diet, microbial metabolites, and immune signaling (1, 4, 10). The strongest evidence for direct mechanistic effects currently comes from animal models, whereas human studies indicate complex and limited diagnosis-specific associations (2, 3, 6). Current findings do not justify presenting gut microbiome dysbiosis as a proven primary cause of ASD. Diet, age, stool characteristics, and individual variation are important confounding factors (3).
Microbiota-mediated neuroimmune modulation has been proposed as a contributor to the etiopathogenesis or symptom expression of ASD and other neurological or behavioral disorders, including anxiety, depression, Alzheimer’s disease, and Parkinson’s disease (10).
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
see also:
Autism spectrum disorders (ASD) & Dysbiosis
Autism Spectrum Disorders (ASD) & Oral Microbiome / Mouth Microbiota
Synbiotics & Autism Spectrum Disorder (ASD)